КардиоСоматика (May 2021)

Pitavastatin: focus on safety and drug interactions

  • Larisa O. Minushkina,
  • Dmitry A. Zateyshchikov

DOI
https://doi.org/10.26442/22217185.2021.1.200634
Journal volume & issue
Vol. 12, no. 1
pp. 48 – 53

Abstract

Read online

Pitavastatin is a drug from the group of HMG-CoA reductase inhibitors, which has good lipid-lowering efficacy and has no significant effect on the risk of diabetes mellitus. This drug is non significantly metabolized by the P450 cytochrome system, which minimizes the risk of possible drug-drug interactions. Peptide organic anionic transporter inhibitors also may affect the efficacy and safety of the drug. This review summarizes the data on the problems of drug interactions of pitavastatin.

Keywords